新型调脂药——多廿烷醇临床应用评价

Clinical assessment of policosanol-a new vegetal drug for regulating serum lipid

多廿烷醇是一种新型调脂药,可以抑制胆固醇合成及提高低密度脂蛋白的血液清除率。降脂效果与他汀类药物相似,对于特殊人群如老年人、肝病患者,其临床有效性、安全性和耐受性已经为多个临床研究证实。与他汀类、贝特类药物联合应用安全性良好。可作为高胆固醇血症、高低密度脂蛋白胆固醇血症或低高密度脂蛋白胆固醇血症患者一级预防治疗用药和不能耐受其他降脂药物的二级预防治疗用药。多廿烷醇对动脉粥样硬化危险因素的长期临床作用还需要进一步研究。

Sumrnary：Policosanol is a new drug for regulating lipid, which can inhibit eholesterin synthesis and increase blood clearance of low-density lipoprotein （LDL）. It has similar effect as statins and its clinical efficiency, safety and tolerance for special people such as the old and those with hepatopath have been confirmed by many clinical studies. Polieosanol combined with statins or fibrates is also safe,which can be used as primary prevention for the patients with hypercholesterinemia, high low-density lipoprotein-cholesterolor low high-density lipoprotein-cholesterol and as secondary prevention for the patients who could not tolerate other lipid-regulating drugs. The longterm clinical effect of Policosanol on the risk factors of atherosclerosis need further researches.